IRE
Conditions
Brief summary
Irreversible electroporation is a non-thermal ablative technology that uses high-voltage electric pulses to create permanent nanopores in tumor cell membranes, leading to apoptosis or other forms of cell death. Because the mechanism is primarily non-thermal, IRE may better preserve extracellular matrix, bile ducts, vessels, and other critical structures than thermal ablation, which is relevant for tumors adjacent to major vascular or biliary anatomy. The main anticipated clinical value of IRE in these protocols is local disease control and potential survival benefit when used after induction therapy in patients with non-progressive disease. The procedure may be performed by open or percutaneous access according to tumor location, safety considerations, and institutional expertise. Perioperative management, imaging guidance, and post-procedure monitoring will follow institutional standards. Post-IRE gastrointestinal dysfunction may occur. Symptom-directed supportive care, including electroacupuncture where appropriate and approved by the investigator, may be used as supportive management. Such care is not intended to replace oncologic treatment and will be recorded as concomitant treatment when administered.
Interventions
OTHERIRE+chemotherapy
IRE+chemotherapy
OTHERchemotherapy
IRE+chemotherapy
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
\- Age 18-75 years, both sexes Histologically or cytologically confirmed locally advanced perihilar cholangiocarcinoma (Bismuth-Corlette type III/IV or equivalent) Non-progressive disease (PR or SD) after 3 cycles of standard induction chemotherapy MDT-confirmed unresectable disease after induction therapy No prior palliative systemic therapy At least one measurable lesion per RECIST 1.1 ECOG Performance Status 0-1 Adequate organ and marrow function: Hb ≥9.0 g/dL, ANC ≥1.5×10⁹/L, platelets ≥100×10⁹/L, TBIL ≤3×ULN, AST/ALT ≤5×ULN, serum creatinine ≤1.5×ULN or CrCl \>60 mL/min Life expectancy ≥3 months Willing to use contraception if of childbearing potential Written informed consent
Exclusion criteria
\- Refusal to receive systemic chemotherapy or possible surgery Metastasis to liver, peritoneum, lung, bone, brain, or other distant sites History of other malignancies (except cured basal cell carcinoma or cervical carcinoma in situ) Severe uncontrolled comorbidities (e.g., NYHA III/IV heart failure, unstable angina, uncontrolled arrhythmia, uncontrolled hypertension, active infection, uncontrolled diabetes, significant effusions, severe portal hypertension, gastric outlet obstruction, respiratory insufficiency) Major surgery within 30 days before screening EGFR monoclonal antibody or EGFR-TKI within 30 days before screening Allergy to any protocol-related drug or component Known HIV infection or chronic hepatitis B/C (active) Unresolved toxicity ≥CTCAE grade 2 from prior treatment (except anaemia, alopecia, skin pigmentation, or chemotherapy-induced neuropathy) Any condition judged by the investigator to make participation inappropriate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 1year | time from first antitumor treatment to death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 1year | Progression-free survival (PFS) |
| DCR ORR | 3MONTH | RECIST 1.1 |
Countries
China
Contacts
CONTACTHuikai Li
Outcome results
None listed